Use of rituximab in lymphomatoid granulomatosis with isolated central nervous system involvement

BMJ Case Rep. 2020 Sep 7;13(9):e235412. doi: 10.1136/bcr-2020-235412.

Abstract

A 33-year-old woman presented to the emergency room with severe headaches. A CT scan of the head revealed two brain lesions with associated vasogenic oedema. Diagnostic resection of one of the lesions followed by pathological analysis revealed grade III lymphomatoid granulomatosis (LYG). Staging investigations elsewhere in the body were negative, isolating this case of LYG to the central nervous system, an atypical presentation. After the resection, she was treated with single-agent rituximab 375 mg/m2 The follow-up MRI demonstrated the resolution of brain lesions and no progression of the disease.

Keywords: haematology (drugs and medicines); malignant and benign haematology; malignant disease and immunosuppression; neurooncology; neurosurgery.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Brain Neoplasms / drug therapy*
  • Female
  • Humans
  • Lymphomatoid Granulomatosis / drug therapy*
  • Rituximab / therapeutic use*

Substances

  • Antineoplastic Agents, Immunological
  • Rituximab